Description
A selective antagonist of NR1A/NR2B subunit-containing NMDA receptors (IC50 = 340 nM); selective for NR1A/NR2B subunit-containing NMDA receptors over those containing NR1A/NR2A or NR1A/NR2C subunits (IC50s = 20 and >100 µM, respectively); binds to σ1 receptors, emopamil binding protein, and fungal C-8 sterol isomerase/ERG2 (Kis = 2, 5, and 1 nM, respectively), as well as α1-ARs (IC50 = 110 nM), 5-HT1A and 5-HT2 (IC50s = 238 and 610 µM, respectively); inhibits infection of MDCK cells by H1N1 and H3N2 influenza isolates in vitro (EC50s = 7.2 and 12.1 µM, respectively); increases NGF, BDNF, and GDNF production in primary mouse astrocytes at 150 µM; reduces maximal electroshock seizures in mice (ED50s = 16 and 7 mg/kg, respectively)
Formal name: α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidineethanol, 2R,3R-dihydroxybutanedioate (2:1)
Synonyms: NP-120
Molecular weight: 400.5
CAS: 23210-58-4
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Ion Channel Modulation|Blockers||Product Type|Biochemicals|Receptor Pharmacology||Research Area|Cell Biology|Cell Signaling|Growth Factor Receptors||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Influenza||Research Area|Neuroscience|Seizure Disorders